Clin Osteol 2008; 13(4): 172-174

Claudin-16 and claudin-19 and their roles in mineral homeostasisReview articles

S. Skálová, ©. Kutilek

Claudins are transmembrane tight junction proteins. They determine the barrier properties of intercellular contact existing between the two neighbouring cells and control the selectivity of paracellular transport. Claudins can therefore significantly affect mineral ho­ meostasis. Claudin-16 (CLDN16) and claudin-19 (CLDN19) regulate the paracellular transport of calcium and magnesium in the loop of Henle. Claudin-16 is defective in autosomal recessive familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (FHHNC), resulting in renal insufficiency Mutations in CLDN19 lead to FHHNC, renal failure and severe ocular abnormalities. This review provides basic information on CLDN16 and CLDN19 and on the clinical manifestations of CLDN16 a

Keywords: claudin-16, claudin-19, hypercalciuria, nephrocalcinosis, hypermagnesiuria, hypomagnesaemia

Published: December 11, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Skálová S, Kutilek ©. Claudin-16 and claudin-19 and their roles in mineral homeostasis. Osteologický bulletin. 2008;13(4):172-174.
Download citation

References

  1. Bushinsky DA Calcium, magnesium, and phosphorus: renal handling and urinary excretion. In: Favus MJ, ed: Primer on the metabolic bone disease and disord of mineral metabolism. 5th ed. Washington, American Society for Bone and Mi­ neral Research, 2003:97-105.
  2. Rude RK. Magnesium metabolism and deficiency. Endocrinol Metab Clin N Amer 1993;22:377-395. Go to original source...
  3. Van Itallie CM, Anderson Physiology 2004;19:331-338. Go to original source...
  4. Krause G, Winkler L, Mueller SL e chim Biophys Acta 2008;1778:631-645. Go to original source...
  5. Simon DB, Lu Y, Choate KA, Velazquez H et al. Pracellin-1, a renal tightjunc on protein required for paracellular Mg2+ resorption. Science 1999;285:103-106. Go to original source...
  6. Weber S, Schlingmann KP, Peters M et al. Primary gene st of rodent paracellin-1. J Am Soc Nephrol 2001;12:2664-2672. Go to original source...
  7. Blanchard A, Jeunemaitre X, Coudol P et al. Pracellin-1 is critical for mag um and calcium reabsorption in the human thick ascending limb of Henle. Kidney Int 2001;59:2206-2215. Go to original source...
  8. Ikari A, Ito M, Okude C et al. Claudin-16 is directly phosphorylated by protein nase A independently of a vasodilator-stimulated phosphoprotein-mediated path­ way. J Cell Physiol 2008;214:221-229. Go to original source...
  9. Himmerkus N, Shan Q, Goerke B et al. Salt- and acid/base metabolism in claudin16 knockdown mice impact for the pathophysiology of FHHNC patients. Am J Physiol Renal Physiol. 2008; Sep 10 (Epub ahead of print) Go to original source...
  10. Hou J, Paul DL, Goodenough DA Paracellin-1 and the modulation of ion selecti­ vity of tight junctions. J Cell Sci 2005;118:5109-5118. Go to original source...
  11. Hou J, Renigunta A, Konrad M et al. Claudin-16 and claudin-19 interact and form a cation-selective tightjunction complex complex. J Clin Invest 2008;118:619-628 Go to original source...
  12. Gunzel D, Yu AS. Function and regulation of claudins in the thick ascending lo­ op of Henle Pflugers Arch. 2008; Sep 16 (Epub ahead of print) Go to original source...
  13. Angelow S, El-Husseini R, Kanzawa SA, Yu AS. Renal localization and function of the tight of the tight junction protein, claudin-19. Am J Physiol Renal Physiol 2007;293:166-177. Go to original source...
  14. Konrad M, Weber S. Recent advances in molecular genetics of hereditary magne­ sium-losing disorders. J Am Soc Nephrol 2003;14:249-260. Go to original source...
  15. Konrad M, Schlingmann KP, Gudermann T. Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 2004;286:599-605. Go to original source...
  16. Weber S, Hoffmann K, Jeck N et al. Familial hypomagnesaemia with hypercalci­ uria and nephrocalcinosis maps to chromosome 3q27 and is associated with mu­ tations in the PCLN-1 gene. Eur J Hum Genet 2000;8:414-422. Go to original source...
  17. Weber S, Schneider L, Peters M. Novel paracellin-1 mutations in 25 fam familial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2001;12:1872-1881. Go to original source...
  18. Kuwertz-Broking E, Frund S, Bulla M, Kleta R, August C, Kisters K. Familial pomagnesemia-hypercalciuria in 2 siblings. Clin Nephrol 2001;56:155-161.
  19. Kang JH, Choi HJ, Cho HY et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis associated with CLDN16 mutation. Pediatr Nephrol 2005;20:1490-1493. Go to original source...
  20. Tasic V, Dervisov D, Koceva S, Weber S, Konrad M. Hypomagnesemia with hy­ percalciuria and nephrocalcinosis: case report and a family study. Jfediatr Nep 2005;20:1003-1006. Go to original source...
  21. Turkmen M, Kasap B, Soylu A et al. Pracellin-1 gene mutation with multiple congenital abnormalities. Pediatr Nephrol 2006;21:1776-1778. Go to original source...
  22. Al-Elq AH. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis in 2 sisters. Saudi Med J 2008;29:447^51
  23. Jferu H, Akin F, Elmas S, Elmaci AM, Konrad M. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis: report of three Turkish siblings. Pediatr Nephrol 2008;23:1009-1012 Go to original source...
  24. Vargas-Poussou R, Cochat P, Le Pottier N et al. Report of a family with two ferent hereditary diseases leading to early nephrocalcinosis. Pediatr Nephrol 2008;23:149-153. Go to original source...
  25. Hampson G, Konrad MA, Scoble J. Familial hypomagnesaemia with hypercalciu­ ria and nephrocalcinosis (FHHNC): compound heterozygous mutation in the claudin 16 (CLDN16) gene. BMC Nephrol 2008;9:12 (Epub ahead of print). Go to original source...
  26. Tajima T, Nakae J, Fujieda K. Two heterozygous mutations of CLDN16 in a Ja­ panese patient with FHHNC. Pediatr Nephrol 2003;18:1280-1282. Go to original source...
  27. Staiger K, Staiger H, Haas C et al. Hypomagnesemia and nephrocalcinosis tient with two heterozygous mutations in the CLDN16 gene. J Nephrol 2007;20: 107-110. Go to original source...
  28. Muller D, Kausalya PJ, Claverie-Martin F et al. A novel claudin 16 mutation sociated with childhood hypercalciuria abolishes binding to ZO-1 and results in lysosomal mistargeting. Am J Hum Genet 2003;73:1293-12301. Go to original source...
  29. Konrad M, Hou J, Weber S et al. CLDN16 genotype predicts renal decli milial hypomagnesemia with hypercalciuria and nephrocalcinosis. J Am Soc Nephrol 2008;19:171-181. Go to original source...
  30. Wolf MT, Dotsch J, Konrad M et al. Follow-up of five patients with FHHNC to mutations in the Pracellin-1 gene. Jfediatr Nephrol 2002;17:602-608. Go to original source...
  31. Zimmermann B, Plank C, Konrad M et al. Hydrochlorothiazide in CLDN16 mu­ tation. Nephrol Dial Transplant 2006;21:2127-2132. Go to original source...
  32. Kutluturk F, Temel B, Uslu B et al. An unusual patient with hypercalciuria current nephrolithiasis, hypomagnesemia and G227R mutation of Paracellin-1. An unusual patient with hypercalciuria and hypomagnesemia unresponsive to thiazi­ de diuretics. Horm Res 2006;66:175-181. Go to original source...
  33. Muller D, Kausalya PJ, Bockenhauer D et al. Unusual clinical presentation and possible r 3076-3079.
  34. Muller D, Kausalya PJ, Meij IC, Hunziker W. Familial hypomagnesemia with hy­ percalciuria and nephrocalcinosis: blocking endocytosis restores surface expressi­ on of a novel Claudin-16 mutant Hum Mol Genet 2006;15:1049-1058. Go to original source...
  35. Kausalya PJ, Amasheh S, Gunzel D et al. Disease-associated mutations affect in­ tracellular traffic an vest 2006;116:878-891. Go to original source...
  36. Konrad M, Schaller A, Seelow D et al. Mutations in the tight-junction gene din 19 (CLDN19) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. Am J Hum Genet 2006;79:949-957. Go to original source...




Clinical Osteology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.